Table 1 Tac1 and TRPV1 SNP frequencies in benign and malignant MS patients.
From: TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis
Clinical/demographic details | Benign MS | Malignant MS | ||||
|---|---|---|---|---|---|---|
Sample size (n) | 112 | 51 | ||||
Sex ratio (F:M) | 87:25 (3.48:1) | 30:21 (1.43:1) | ||||
Mean age of onset (y) | 25.1 | 37.3 | ||||
Mean duration of disease (y) | 26 | 3.6 | ||||
SNP | Frequency (benign MS) | Frequency (malignant MS) | Allele tested | Chi | p Value (nominal) | Odds ratio (95% CI) |
rs6465606 (Tac1) | 0.25 | 0.29 | A | 0.81 | 0.37 | 1.21 (0.80–1.84) |
rs4526299 (Tac1) | 0.16 | 0.15 | T | 0.15 | 0.70 | 0.90 (0.54–1.52) |
rs877610 (TRPV1) | 0.04 | 0.09 | T | 5.43 | 0.02 | 2.43 (1.13–5.21) |
rs8065080 (TRPV1) | 0.34 | 0.30 | C | 0.53 | 0.47 | 0.86 (0.58–1.29) |
rs224534 (TRPV1) | 0.35 | 0.44 | A | 3.18 | 0.07 | 1.42 (0.97–2.07) |